IFP Advisors Inc Increases Stock Holdings in GSK plc (NYSE:GSK)

IFP Advisors Inc boosted its position in shares of GSK plc (NYSE:GSK) by 113.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,392 shares of the pharmaceutical company’s stock after acquiring an additional 6,578 shares during the quarter. IFP Advisors Inc’s holdings in GSK were worth $419,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Indiana Trust & Investment Management Co boosted its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its stake in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the period. Finally, Sierra Ocean LLC purchased a new position in shares of GSK in the 4th quarter valued at about $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Up 0.8 %

GSK opened at $37.59 on Friday. The firm has a market cap of $77.90 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The business’s 50 day moving average is $34.99 and its two-hundred day moving average is $37.26. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.18%. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 98.74%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.